Core Viewpoint - Aoxiang Pharmaceutical (603229) reported a decline in net profit and revenue for the first half of 2025, indicating challenges in financial performance compared to the previous year [1] Financial Performance Summary - Total revenue for H1 2025 was 482 million yuan, a decrease of 2.14% year-on-year [1] - Net profit attributable to shareholders was 169 million yuan, down 5.83% year-on-year [1] - In Q2 2025, total revenue was 175 million yuan, reflecting an 8.48% decline year-on-year [1] - Q2 net profit was 50.15 million yuan, a significant drop of 25.54% year-on-year [1] Key Financial Metrics - Gross margin stood at 58.16%, a decrease of 2.76% year-on-year [1] - Net margin was 35.14%, down 3.77% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 38.91 million yuan, accounting for 8.07% of revenue, a slight increase of 0.13% year-on-year [1] - Earnings per share (EPS) was 0.20 yuan, a decrease of 9.09% year-on-year [1] - Cash flow per share was 0.05 yuan, down 16.7% year-on-year [1] Asset and Liability Overview - Cash and cash equivalents increased to 1.147 billion yuan, a rise of 15.89% year-on-year [1] - Accounts receivable decreased to 280 million yuan, down 8.62% year-on-year [1] - Interest-bearing debt rose to 331 million yuan, an increase of 64.41% year-on-year [1] Investment Return Metrics - The company's return on invested capital (ROIC) for the previous year was 7.79%, indicating average capital returns [3] - Historical median ROIC since listing is 11.16%, suggesting generally good investment returns [3] Debt Servicing Capability - The company maintains a healthy cash asset position, indicating strong debt servicing capability [3] Accounts Receivable Concern - The accounts receivable to profit ratio has reached 135.48%, suggesting potential issues in collection efficiency [4] Analyst Expectations - Analysts project 2025 earnings to be around 271 million yuan, with an average EPS forecast of 0.33 yuan [4]

Group 1 - The board of directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd. held its eighth meeting of the fourth session on August 28, 2025, in a combined onsite and remote format [1][2] - The meeting was attended by 9 directors, and all resolutions were passed unanimously with 9 votes in favor, 0 against, and 0 abstentions [2] - The board approved the 2025 semi-annual report and its summary, the special report on the use of raised funds, the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement" action plan, and the revision of the "Information Disclosure Delay and Exemption Management System" [2][3] Group 2 - The resolutions included the approval of the semi-annual report which had been reviewed by the audit committee [2] - The special report on the use of raised funds was also approved, with details available on the Shanghai Stock Exchange website and relevant financial newspapers [2] - The board's actions reflect a commitment to transparency and adherence to regulatory requirements [1][3]

Core Viewpoint - The company, Zhejiang Ausun Pharmaceutical Co., Ltd., is preparing for its 2025 semi-annual performance briefing to provide investors with insights into its operational results and financial status for the first half of 2025 [6][7][10]. Company Overview - The company is identified by the stock code 603229 and is referred to as Ausun Pharmaceutical [5]. - The company has confirmed that all board members attended the board meeting [2]. Financial Data - The semi-annual report is unaudited [3]. - The company has not proposed any profit distribution or capital reserve conversion plans for the reporting period [4]. Important Matters - The company has indicated that there are no significant changes in its operational situation during the reporting period, nor any events that would have a major impact on its operations [4]. Investor Communication - The performance briefing is scheduled for September 9, 2025, from 15:00 to 16:00, and will be held at the Shanghai Stock Exchange Roadshow Center [6][8]. - Investors can submit questions for the briefing from September 2 to September 8, 2025, through the Roadshow Center's website or via email [6][9]. Fundraising and Usage - The company has conducted non-public stock offerings in 2020 and 2022, raising approximately RMB 420 million and RMB 485 million respectively, with net proceeds after expenses being RMB 408 million and RMB 474 million [11][12]. - As of June 30, 2025, the company has two fundraising special accounts for the 2020 offering and five for the 2022 offering [14][15]. - The company has utilized RMB 8 million of idle fundraising temporarily to supplement working capital, with RMB 6 million still outstanding as of June 30, 2025 [18][19]. - The company has not engaged in cash management or investment of idle funds during the reporting period [20]. Board and Supervisory Meetings - The fourth board meeting was held on August 28, 2025, where the semi-annual report and fundraising usage report were approved unanimously [36][39]. - The supervisory board also convened on the same day and approved the same reports, confirming their compliance with relevant laws and regulations [45][49].

Core Viewpoint - Aoxiang Pharmaceutical announced the approval of several proposals, including the 2025 semi-annual report and its summary, during the eighth meeting of the fourth board of directors [2] Group 1 - The company held its fourth board of directors' eighth meeting on August 28 [2] - The meeting resulted in the approval of the 2025 semi-annual report and its summary [2]

Group 1 - The company announced the approval of the proposal regarding the 2025 semi-annual report and its summary during the seventh meeting of the fourth supervisory board [2]

二、监事会会议审议情况 经全体监事认真审议并表决，一致通过了如下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 监事会认为：公司 2025 年半年度报告的编制和审议程序符合相关法律、法 规、公司章程和公司内部管理制度的各项规定。2025 年半年度报告真实、准确、 完整地反映了公司的财务状况和经营成果。在提出本意见前，未发现参与 2025 年半年度报告编制和审议的人员有违反保密规定的行为。 证券代码：603229 证券简称：奥翔药业 公告编号：2025-036 浙江奥翔药业股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江奥翔药业股份有限公司（以下简称"公司"）第四届监事会第七次会议 于 2025 年 8 月 28 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司新 办公楼一楼会议室以现场的方式召开。会议通知已于 2025 年 8 月 16 日以专人送 达或电子邮件方式送交公司全体监事。本次会议应参加监事 3 人，实际参加监 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江奥翔药业股份有限公司（以下简称"公司"）第四届董事会第八次会议 于 2025 年 8 月 28 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司新 办公楼一楼会议室以现场与通讯相结合的方式召开。会议通知已于 2025 年 8 月 16 日以专人送达或电子邮件方式送交公司全体董事。本次会议应参加董事 9 人， 实际参加董事 9 人，会议由公司董事长郑志国先生主持，公司全体监事及高级管 理人员列席了本次会议。会议的通知、召集、召开和表决程序符合《中华人民共 和国公司法》《公司章程》等有关法律、法规的规定。 二、董事会会议审议情况 经全体董事认真审议并表决，一致通过了如下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 本议案已经审计委员会审议通过，并同意提交公司董事会审议。 证券代码：603229 证券简称：奥翔药业 公告编号：2025-035 浙江奥翔药业股份有限公司 第四届董事会第八次会议决议公告 项报告的议案》 具体内 ...

格隆汇8月28日丨奥翔药业(603229.SH)公布2025年半年度报告，报告期内，公司实现营业收入4.82亿 元，同比下降2.14%；归属于上市公司股东的净利润1.69亿元，同比下降5.83%；归属于上市公司股东的 扣除非经常性损益的净利润1.51亿元，同比下降12.29%；基本每股收益0.20元。 ...

Group 1 - The company reported a revenue of 482 million yuan for the first half of 2025, representing a year-on-year decrease of 2.14% [1] - The net profit attributable to the parent company was 169 million yuan, down 5.83% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 151 million yuan, reflecting a year-on-year decline of 12.29% [1] - The basic earnings per share stood at 0.20 yuan [1]

第五条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息 涉及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以 下统称"国家秘密"），依法豁免披露。 第一章 总则 浙江奥翔药业股份有限公司 信息披露暂缓与豁免业务管理制度 第一条 为规范浙江奥翔药业股份有限公司（以下简称"公司"）和其他信 息披露义务人信息披露暂缓、豁免行为，加强信息披露监管，保护投资者合法权 益，根据《中华人民共和国保守国家秘密法》《中华人民共和国证券法》《上市公 司信息披露管理办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易 所股票上市规则》等法律、行政法规和规章，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证监会和上海证券交易所规定或者要求披露的内容，适 用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操纵市场等违法行为。 第二章 信息披露暂缓与豁免的适用情形 第四条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事项， ...